Amneal制药 AMRX 深 沪
等待开盘 07-01 09:30:00 美东时间
17.31
+0.020
+0.12%
华盛通- 最 高17.49
- 今 开17.30
- 成交量 225.86万股
- 最 低 17.17
- 昨 收 17.29
- 总市值 55.22亿
- 52周最高 17.86
- 市盈率 静 78.04
- 换手率 0.71%
- 52周最低 7.665
- 委 比 69.87%
- 总股本 3.19亿
- 历史最高 24.48
- 量 比 0.66
- 振 幅 1.85%
- 历史最低 1.24
- 每 手 1
- 风险率 2.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness
The U.S. Food and Drug Administration (FDA) on Monday named seven companies selected for its FDA PreCheck Pilot Program. The initiative aims at strengthening domestic pharmaceutical manufacturing, improving the resilience of the U.S. drug supply chain and providing companies with earlier regulatory ...
06-30 22:17
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Hopledo® for treating Parkinson's disease in Europe. Based on the Phase 3 RISE-PD trial, Hopledo® showed significant improvement in "Good ON" time with fewer doses compared to immediate-release levodopa/carbidopa. Already approved in the U.S. as CREXONT®, Hopledo® combines immediate and extended-release formulations for sustained efficacy. With over one million ...
06-29 07:00
FOCUS-US progesterone supplies tighten as menopause treatment demand grows
FOCUS-US progesterone supplies tighten as menopause treatment demand grows By Mrinalika Roy and Sriparna Roy June 17 (Reuters) - U.S. supplies of progesterone are coming under strain, with patients, clinicians, and pharmacists reporting recent intermittent shortages of oral versions of the hormone u
06-17 18:00
Top 3 Health Care Stocks That May Collapse This Quarter
As of June 15, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices ...
06-15 20:51
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- Dispensary of Hop...
06-10 22:09
Amneal Pharmaceuticals Announces New Interim Results From Phase 4 Study Reinforcing Reported Benefits Of Parkinson's Treatment Crexont
Overall Interim Findings (Entire Study Population, 214Patients; Six-Week Analysis)All 214 patients who switched to CREXONT (mean age 67.1±9.07 years):Increased Daily "Good On" Time:+3.33 hours when switching from IR
06-05 20:02
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study, showing that CREXONT (carbidopa and levodopa) extended-release capsules provide clinically meaningful benefits for Parkinson’s disease patients. The study of 214 patients demonstrated significant increases in daily “Good On” time, reductions in “Off” time, and improved motor function across all prior treatment groups. Patients switching from RYTARY experi...
06-05 12:00
Amneal Pharmaceuticals Romidepsin Injection Solution Receives FDA Approval
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's romidepsin injection solution, 27.5 mg/5.5 mL, supplied
06-04 20:05
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Amneal Pharmaceuticals received FDA approval for its ready-to-use romidepsin injection solution, offering a convenient alternative to lyophilized powder. As a Competitive Generic Therapy, it secures 180 days of market exclusivity and strengthens Amneal's injectables portfolio. The product eliminates reconstitution steps, improving safety and efficiency for healthcare providers. Romidepsin is indicated for cutaneous T-cell lymphoma and has common ...
06-04 12:00
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
